Literature DB >> 28621337

Diabetes: SGLT2 inhibitors and diabetic ketoacidosis - a growing concern.

Guillermo E Umpierrez1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28621337     DOI： 10.1038/nrendo.2017.77

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  8 in total

1.  SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.

Authors:  Gian Paolo Fadini; Benedetta Maria Bonora; Angelo Avogaro
Journal:  Diabetologia       Date:  2017-05-12       Impact factor: 10.122

2.  Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.

Authors:  Robert R Henry; Payal Thakkar; Cindy Tong; David Polidori; Maria Alba
Journal:  Diabetes Care       Date:  2015-10-20       Impact factor: 19.112

3.  The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.

Authors:  Helena W Rodbard; Anne L Peters; April Slee; Anjun Cao; Shana B Traina; Maria Alba
Journal:  Diabetes Care       Date:  2016-11-29       Impact factor: 19.112

4.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 5.  Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia.

Authors:  Guillermo Umpierrez; Mary Korytkowski
Journal:  Nat Rev Endocrinol       Date:  2016-02-19       Impact factor: 43.330

Review 6.  SGLT inhibitors in management of diabetes.

Authors:  Abd A Tahrani; Anthony H Barnett; Clifford J Bailey
Journal:  Lancet Diabetes Endocrinol       Date:  2013-08-13       Impact factor: 32.069

7.  Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.

Authors:  Ngozi Erondu; Mehul Desai; Kirk Ways; Gary Meininger
Journal:  Diabetes Care       Date:  2015-07-22       Impact factor: 19.112

8.  Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet.

Authors:  Tomohide Hayami; Yoshiro Kato; Hideki Kamiya; Masaki Kondo; Ena Naito; Yukako Sugiura; Chika Kojima; Sami Sato; Yuichiro Yamada; Rina Kasagi; Toshihito Ando; Saeko Noda; Hiromi Nakai; Eriko Takada; Emi Asano; Mikio Motegi; Atsuko Watarai; Koichi Kato; Jiro Nakamura
Journal:  J Diabetes Investig       Date:  2015-02-20       Impact factor: 4.232
  8 in total
  6 in total

Review 1.  Management of Diabetes in Patients Undergoing Bariatric Surgery.

Authors:  Christopher M Mulla; Harris M Baloch; Samar Hafida
Journal:  Curr Diab Rep       Date:  2019-11-04       Impact factor: 4.810

Review 2.  A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA.

Authors:  Omar Sheikh; Mouhamed Nashawi; Ayman Battisha; Robert Chilton
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-05-15

3.  Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.

Authors:  Peter Ueda; Henrik Svanström; Mads Melbye; Björn Eliasson; Ann-Marie Svensson; Stefan Franzén; Soffia Gudbjörnsdottir; Kristian Hveem; Christian Jonasson; Björn Pasternak
Journal:  BMJ       Date:  2018-11-14

4.  How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.

Authors:  Agnes Bosch; Christian Ott; Susanne Jung; Kristina Striepe; Marina V Karg; Dennis Kannenkeril; Thomas Dienemann; Roland E Schmieder
Journal:  Cardiovasc Diabetol       Date:  2019-03-29       Impact factor: 9.951

5.  Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.

Authors:  Yotsapon Thewjitcharoen; Nalin Yenseung; Areeya Malidaeng; Soontaree Nakasatien; Phawinpon Chotwanvirat; Sirinate Krittiyawong; Ekgaluck Wanothayaroj; Thep Himathongkam
Journal:  Diabetol Metab Syndr       Date:  2017-12-01       Impact factor: 3.320

Review 6.  The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.

Authors:  Emily Brown; John P H Wilding; Uazman Alam; Thomas M Barber; Janaka Karalliedde; Daniel J Cuthbertson
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.